Glenmark Pharmaceuticals announced its financial results for the second quarter ended September 30, 2021. For the second quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs 31,474 million as against Rs 29,525 million recordings an increase of 6.6%.
 
Consolidated EBITDA was at Rs 5,902 million in the quarter ended September 30, 2021, as against Rs 5,699 million in the previous corresponding quarter, registering an increase of 6.8 per cent.
 
Profit after Tax (PAT) was at Rs 2,577 million for the quarter ended September 30, 2021, as compared to Rs 2,340 million in the previous corresponding quarter, recording a growth of 10.1 per cent.
 
“We delivered yet another quarter of consistent performance, both in revenue growth and profitability. We have continued to perform well in our core therapy areas and launched differentiated products,” said Glenn Saldanha, CMD, Glenmark Pharmaceuticals.

He further added, “We have substantially reduced our debt through a
combination of internal accruals and IPO proceeds. We are focused on enhancing free cash generation and achieving our strategic objectives going forward."